Loading...

Biogen Inc.

BIIBNASDAQ
Healthcare
Drug Manufacturers - General
$131.52
$-1.07(-0.81%)

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 76.9/100

Key Financials

Market Cap19.3B
P/E Ratio13.03
EPS (TTM)$10.12
ROE0.09%
Fundamental Analysis

AI Price Forecasts

1 Week$133.63
1 Month$131.28
3 Months$123.21
1 Year Target$127.25

BIIB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biogen Inc. (BIIB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $127.25.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.03 and a market capitalization of 19.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;